| Product Code: ETC13203752 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market was valued at USD 5.6 Billion in 2024 and is expected to reach USD 12.2 Billion by 2031, growing at a compound annual growth rate of 3.90% during the forecast period (2025-2031).
The Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth due to the increasing demand for personalized medicine and advanced therapies. CDMOs play a crucial role in providing specialized services for the development, manufacturing, and commercialization of cell and gene therapies, catering to the unique requirements of biotechnology and pharmaceutical companies. Factors such as the complexity of manufacturing processes, regulatory requirements, and the need for expertise in cell and gene therapy production have driven the outsourcing of these services to CDMOs. Market players are focusing on expanding their capabilities, capacities, and geographic presence to meet the growing demand. Additionally, collaborations between CDMOs and biopharmaceutical companies are increasing, further driving the market growth. The market is expected to continue expanding rapidly as cell and gene therapies gain traction in the healthcare industry.
The Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth driven by the increasing demand for personalized medicines and the rise in biopharmaceutical R&D activities. Key trends include the expansion of CDMOs` capabilities to meet the complex manufacturing requirements of cell and gene therapies, as well as the adoption of innovative technologies such as automation and digital solutions to enhance production efficiency. Opportunities in the market lie in strategic partnerships and collaborations between CDMOs and biopharmaceutical companies, as well as the growing investments in advanced manufacturing facilities to cater to the rising demand for cell and gene therapy products. Overall, the market presents promising growth prospects for CDMOs that can provide high-quality, flexible, and cost-effective manufacturing solutions for the rapidly evolving cell and gene therapy landscape.
One of the key challenges faced in the Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is the complex and rapidly evolving regulatory landscape. The regulatory requirements for cell and gene therapies are stringent and vary across different regions, requiring CDMOs to navigate a complex web of compliance standards to ensure the safety, quality, and efficacy of the therapies they develop and manufacture. Keeping up with the ever-changing regulations, especially in emerging markets, can pose significant challenges for CDMOs, leading to delays in product development, increased costs, and potential compliance issues. Additionally, the dynamic nature of the regulatory environment can make long-term planning and investment decisions more challenging for CDMOs in this market.
The Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market is primarily driven by the increasing demand for personalized medicine and targeted therapies, leading to a growing number of cell and gene therapy products in development. The complexity of manufacturing these therapies necessitates specialized expertise and infrastructure, prompting companies to outsource to Contract Development and Manufacturing Organizations (CDMOs) for cost-effective and efficient production. Additionally, regulatory support and initiatives to expedite the approval process for cell and gene therapies are fueling market growth. Moreover, advancements in bioprocessing technologies and the adoption of innovative manufacturing strategies by CDMOs are further driving the market expansion, as companies seek to leverage the expertise and capabilities of specialized service providers to accelerate the commercialization of their therapies.
Government policies related to the Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market are primarily focused on ensuring safety, efficacy, and quality standards in the development and manufacturing of these advanced therapies. Regulatory bodies such as the FDA in the United States and the EMA in Europe have established guidelines and requirements that CDMOs must adhere to in order to operate in this market. These policies include stringent oversight of manufacturing processes, facility standards, and product quality control measures to safeguard patient health and promote innovation in the field of cell and gene therapy. Additionally, governments may offer incentives or funding support to encourage the growth of this market and accelerate the development of new therapies.
The Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is poised for significant growth in the coming years. With the increasing focus on personalized medicine and innovative treatment modalities, the demand for contract development and manufacturing services in the cell and gene therapy space is expected to surge. Key drivers include the expanding pipeline of cell and gene therapy products, growing investments in this sector, and the need for specialized expertise and infrastructure. Additionally, advancements in technology and regulations supporting the development of these therapies are likely to further propel market growth. As a result, the Global Cell and Gene Therapy CDMO market is anticipated to experience robust expansion, offering substantial opportunities for CDMO providers to capitalize on this burgeoning market segment.
In the Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, different regions showcase unique trends and opportunities. Asia is emerging as a key player due to lower manufacturing costs and a growing focus on innovation. North America leads the market with a strong presence of established CDMOs and a favorable regulatory environment. Europe is witnessing rapid growth driven by increasing investments in biotechnology and favorable government policies. The Middle East and Africa region is experiencing steady growth with a rising interest in cell and gene therapy technologies. Latin America offers potential growth opportunities with a growing number of partnerships and collaborations in the region. Overall, the global market for CDMOs in cell and gene therapy is dynamic, with each region contributing to its expansion in distinct ways.
Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume, 2021 & 2031F |
3.3 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Industry Life Cycle |
3.4 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Porter's Five Forces |
3.5 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.7 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume Share, By Stage, 2021 & 2031F |
3.8 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Trends |
6 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, 2021 - 2031 |
6.1 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Product, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Cell Therapy, 2021 - 2031 |
6.1.3 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Gene Therapy, 2021 - 2031 |
6.2 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Stage, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Pre-clinical, 2021 - 2031 |
6.2.3 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Clinical, 2021 - 2031 |
6.2.4 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Commercial, 2021 - 2031 |
6.3 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Oncology, 2021 - 2031 |
6.3.3 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Cardiovascular Diseases, 2021 - 2031 |
6.3.4 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Infectious Diseases, 2021 - 2031 |
6.3.5 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Genetic Diseases, 2021 - 2031 |
6.3.6 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Neurological Diseases, 2021 - 2031 |
6.3.7 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Others Indications, 2021 - 2031 |
7 North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Overview & Analysis |
7.1 North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
7.2 North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Product, 2021 - 2031 |
7.4 North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.5 North America Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
8 Latin America (LATAM) Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Overview & Analysis |
8.1 Latin America (LATAM) Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Product, 2021 - 2031 |
8.4 Latin America (LATAM) Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Stage, 2021 - 2031 |
8.5 Latin America (LATAM) Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
9 Asia Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Overview & Analysis |
9.1 Asia Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Product, 2021 - 2031 |
9.4 Asia Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Stage, 2021 - 2031 |
9.5 Asia Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
10 Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Overview & Analysis |
10.1 Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Product, 2021 - 2031 |
10.4 Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Stage, 2021 - 2031 |
10.5 Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
11 Europe Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Overview & Analysis |
11.1 Europe Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Product, 2021 - 2031 |
11.4 Europe Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Stage, 2021 - 2031 |
11.5 Europe Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
12 Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Overview & Analysis |
12.1 Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Product, 2021 - 2031 |
12.4 Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Stage, 2021 - 2031 |
12.5 Middle East Cell and Gene Therapy Contract Development and Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
13 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Key Performance Indicators |
14 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Export/Import By Countries Assessment |
15 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Opportunity Assessment |
15.1 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Opportunity Assessment, By Product, 2021 & 2031F |
15.3 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Opportunity Assessment, By Stage, 2021 & 2031F |
15.4 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Opportunity Assessment, By Indication, 2021 & 2031F |
16 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Competitive Landscape |
16.1 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue Share, By Companies, 2024 |
16.2 Global Cell and Gene Therapy Contract Development and Manufacturing Organization Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |